$PIRS News Article - Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific https://marketwirenews.com/news-releases/pier...09478.html
(0)
(0)
Pieris Pharmaceuticals, Inc. (PIRS) Stock Research Links